Effects of Low-Dose Tamoxifen on Breast Cancer Biomarkers
Author Information
Author(s): de Sousa Juarez Antônio, Facina Gil, da Silva Benedito Borges, Gebrim Luiz Henrique
Primary Institution: Division of Breast Diseases, HMI, Goiânia, Brazil; Division of Breast Diseases of the Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
Hypothesis
Can low-dose tamoxifen effectively reduce breast cancer biomarkers?
Conclusion
Tamoxifen significantly reduced Ki-67, estrogen receptor, and progesterone receptor positivity in breast cancer patients treated with a low dose.
Supporting Evidence
- Tamoxifen reduced Ki-67 from 24.69% to 10.43%.
- Estrogen receptor positivity decreased from 59.53% to 25.99%.
- Progesterone receptor positivity dropped from 59.34% to 29.59%.
Takeaway
This study shows that taking a small amount of tamoxifen can help lower certain markers in breast cancer, which might mean it's effective even at lower doses.
Methodology
A randomized clinical trial with 38 patients, comparing a control group with a group receiving 10 mg of tamoxifen for 14 days.
Limitations
The study did not include a group treated with 20 mg/day of tamoxifen for comparison.
Participant Demographics
Women with palpable and operable breast tumors, stages I, II, and IIIA.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website